Literature DB >> 7691343

An RT-PCR-SSCP screening strategy for detection of mutations in the gene encoding the alpha 1 chain of type I collagen: application to four patients with osteogenesis imperfecta.

K Mackay1, P H Byers, R Dalgleish.   

Abstract

A strategy has been developed to allow the screening for mutations in the cDNA of the type I collagen alpha 1 chain. The method involves polymerase chain reaction amplification of four overlapping segments covering the majority of the sequence coding for alpha 1(I) collagen. Four or five restriction endonuclease digestions are performed for each segment and digested samples subjected to single strand conformation polymorphism analysis. Mutations are finally defined by DNA sequence analysis. The application to the detection of mutations in four patients with lethal and non-lethal forms of osteogenesis imperfecta is described. In each of these patients, the heterozygous mutation identified resulted in substitution of different glycine residues with serines. In addition to these deleterious mutations, several novel silent variants were characterised. The strategy provides a rapid approach to screening for mutations and polymorphisms in alpha 1(I) collagen cDNA and is of general interest in scanning large regions of DNA for sequence changes.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7691343     DOI: 10.1093/hmg/2.8.1155

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  10 in total

1.  Biochemical screening of type I collagen in osteogenesis imperfecta: detection of glycine substitutions in the amino end of the alpha chains requires supplementation by molecular analysis.

Authors:  W A Cabral; S Milgrom; A D Letocha; E Moriarty; J C Marini
Journal:  J Med Genet       Date:  2006-08       Impact factor: 6.318

Review 2.  Targeting defective proteostasis in the collagenopathies.

Authors:  Madeline Y Wong; Matthew D Shoulders
Journal:  Curr Opin Chem Biol       Date:  2019-04-24       Impact factor: 8.822

3.  Three unrelated individuals with perinatally lethal osteogenesis imperfecta resulting from identical Gly502Ser substitutions in the alpha 2-chain of type I collagen.

Authors:  N J Rose; K Mackay; A De Paepe; B Steinmann; H H Punnett; R Dalgleish
Journal:  Hum Genet       Date:  1994-11       Impact factor: 4.132

4.  Substitution of glycine-661 by serine in the alpha1(I) and alpha2(I) chains of type I collagen results in different clinical and biochemical phenotypes.

Authors:  L Nuytinck; R Dalgleish; L Spotila; J P Renard; N Van Regemorter; A De Paepe
Journal:  Hum Genet       Date:  1996-03       Impact factor: 4.132

5.  Destabilization of osteogenesis imperfecta collagen-like model peptides correlates with the identity of the residue replacing glycine.

Authors:  K Beck; V C Chan; N Shenoy; A Kirkpatrick; J A Ramshaw; B Brodsky
Journal:  Proc Natl Acad Sci U S A       Date:  2000-04-11       Impact factor: 11.205

Review 6.  Perinatal lethal osteogenesis imperfecta.

Authors:  W G Cole; R Dalgleish
Journal:  J Med Genet       Date:  1995-04       Impact factor: 6.318

7.  Gly511 to Ser substitution in the COL1A1 gene in osteogenesis imperfecta type III patient with increased turnover of collagen.

Authors:  Anna Galicka; Sławomir Wołczyński; Andrzej Gindzieński; Arkadiusz Surazyński; Jerzy Pałka
Journal:  Mol Cell Biochem       Date:  2003-06       Impact factor: 3.396

8.  Genetic counselling on brittle grounds: recurring osteogenesis imperfecta due to parental mosaicism for a dominant mutation.

Authors:  M Raghunath; K Mackay; R Dalgleish; B Steinmann
Journal:  Eur J Pediatr       Date:  1995-02       Impact factor: 3.183

9.  A Gly238Ser substitution in the alpha 2 chain of type I collagen results in osteogenesis imperfecta type III.

Authors:  N J Rose; K Mackay; P H Byers; R Dalgleish
Journal:  Hum Genet       Date:  1995-02       Impact factor: 4.132

10.  Mutation and polymorphism spectrum in osteogenesis imperfecta type II: implications for genotype-phenotype relationships.

Authors:  Dale L Bodian; Ting-Fung Chan; Annie Poon; Ulrike Schwarze; Kathleen Yang; Peter H Byers; Pui-Yan Kwok; Teri E Klein
Journal:  Hum Mol Genet       Date:  2008-11-07       Impact factor: 6.150

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.